GEMoaB is a biopharmaceutical company based in Dresden/Germany. The company has a broad pipeline of next generation immunotherapy product candidates for the treatment of advanced blood cancers and solid tumours in pre-clinical and clinical development. The company was founded in 2011 by the two university professors Gerhard Ehninger and Michael Bachmann.Get to know GEMoaB, Company Website, Retrieved: May 11, 2020 It was acquired by the new company AvenCell Therapeutics in 2021.
Company background
To overcome the limitations of current cellular immunotherapies, GEMoaB has established two cellular immunotherapy platforms, which are called UniCAR & RevCAR. These genetically modified T-cells can be rapidly and repeatedly turned on and off via dosing of so-called Targeting Modules (TMs), which crosslink UniCAR/RevCAR T-effector cells with malignant target cells. Upon cross-linkage, UniCAR/RevCAR T-cells are activated and expanded and eliminate malignant target cells. They can be rapidly turned off after TM withdrawal, promising to avoid T-effector cell exhaustion and to reduce potential side effects typically associated with CAR-T therapies.
Scientific and strategic board
The company's scientific and strategic board is composed of: Gerhard Ehninger (Chairman), Michael Bachmann (Germany), Katy Rezvani (U.S.A.), Bob Löwenberg (The Netherlands) as well as Thomas de Maizière, Member of Parliament (Germany).Scientific and Strategic Advisory Board, Company Website, Retrieved: May 11, 2020
Co-operations
Gemoab co-operates with a range of partners: its sister company Cellex in Cologne, Germany, the Fraunhofer-Institut, the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the federal Saxonian Ministry of Science and Research.Our Partners, Company Website, Retrieved: May 11, 2020
Drugs currently under development GEM333: T-cell engaging bispecific antibody (TCE) against CD33 in AMLAML: GEM333-01, Nationales Centrum für Tumorerkrankungen Dresden, Retrieved: May 11, 2020Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia, clinicaltrials.gov, Retrieved: May 11, 2020 GEM3PSCA, TCE against PSCA in Prostate Cancer and other PSCA expressing solid tumoursStudy With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker, clinicaltrials.gov, Retrieved: May 11, 2020 UniCAR-T-CD 123 for the treatment of AML, ALL and certain lymphomas UniCAR-T-PSMA for the treatment of a number of PSMA expressing tumours
Literatur .
. .
See also Gene therapy DKMS
References
External links